Analyst Ranking
Top 25%
#1267 out of 5081 analysts
Average Return
+4.2%
Win Rate
42%34 out of 81
Risk vs Reward
Poor
Good

Paul Matteis's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Uniqure NvQURE
+305.69%$17.40$70.59
2024-12-16 -
2025-10-29
Strong Buy
Alto Neuroscience IncANRO
+209.93%$4.53$14.04
2024-11-13 -
2025-10-29
Strong Buy
Sionna Therapeutics IncSION
+153.51%$14.80$37.52
2025-03-04 -
2025-10-29
Strong Buy
Dyne Therapeutics IncDYN
+139.90%$9.85$23.63
2025-07-31 -
2025-10-29
Strong Buy
Rhythm Pharmaceuticals IncRYTM
+115.01%$52.97$113.89
2025-03-05 -
2025-10-29
Strong Buy

Paul Matteis Analyst Color

Get additional color on Paul Matteis's coverage of popular stocks

Paul Matteis's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Neurocrine Biosciences IncNBIX
7Strong Buy$183.00+32.59%Maintains
15 hours ago
Biomarin Pharmaceutical IncBMRN
10Strong Buy$73.00+40.76%Maintains
2 days ago
Alnylam Pharmaceuticals IncALNY
9Strong Buy$495.00+2.78%Maintains
24 days ago
Ionis Pharmaceuticals IncIONS
5Hold$67.00-6.79%Maintains
24 days ago
Lb Pharmaceuticals IncLBRX
1Strong Buy$27.00+72.52%Initiates Coverage On
24 days ago
Pepgen IncPEPG
3Strong Buy$12.00+166.08%Maintains
a month ago
Uniqure NvQURE
2Strong Buy$65.00-7.92%Maintains
a month ago
Vertex Pharmaceuticals IncVRTX
14Hold$455.00+9.06%Maintains
3 months ago
Dyne Therapeutics IncDYN
4Strong Buy$36.00+52.35%Maintains
3 months ago
Rhythm Pharmaceuticals IncRYTM
2Strong Buy$94.00-17.46%Maintains
5 months ago
Vigil Neuroscience IncVIGL
2Hold$8.00-0.62%Downgrades
5 months ago
Neumora Therapeutics IncNMRA
2Hold$2.00-20.00%Downgrades
8 months ago
Sionna Therapeutics IncSION
1Strong Buy$32.00-14.71%Initiates Coverage On
8 months ago
Gh Research PLCGHRS
2Strong Buy$32.00+132.39%Maintains
8 months ago
Compass Pathways PLCCMPS
1Strong Buy$11.00+73.78%Initiates Coverage On
8 months ago
Sage Therapeutics IncSAGE
5Hold$6.00-30.88%Maintains
10 months ago
Denali Therapeutics IncDNLI
3Strong Buy$37.00+127.69%Upgrades
10 months ago
Alector IncALEC
5Hold$4.00+158.06%Downgrades
10 months ago
Alto Neuroscience IncANRO
3Strong Buy$10.00-28.77%Maintains
a year ago
Neurogene IncNGNE
2Strong Buy$60.00+83.65%Maintains
a year ago
Alkermes PLCALKS
5Strong Buy$36.00+14.47%Upgrades
a year ago
Rapport Therapeutics IncRAPP
1Strong Buy$35.00N/AInitiates Coverage On
a year ago
Acadia Pharmaceuticals IncACAD
5Hold$21.00N/AMaintains
a year ago
Contineum Therapeutics IncCTNM
1Strong Buy$29.00N/AInitiates Coverage On
a year ago
Biogen IncBIIB
6Strong Buy$287.00N/AMaintains
2 years ago
Lexeo Therapeutics IncLXEO
1Strong Buy$20.00N/AInitiates Coverage On
2 years ago
Vistagen Therapeutics IncVTGN
1Strong Buy$12.00N/AInitiates Coverage On
2 years ago
Karuna Therapeutics IncKRTX
3Strong Buy$295.00N/AMaintains
3 years ago
Cerevel Therapeutics Holdings IncCERE
2Strong Buy$54.00N/AMaintains
3 years ago
Athira Pharma IncATHA
2Hold$50.00N/ADowngrades
3 years ago
Kalvista Pharmaceuticals IncKALV
1Strong Buy$32.00N/AMaintains
3 years ago
Climb Bio IncCLYM
1Strong Buy$35.00N/AInitiates Coverage On
4 years ago
Acumen Pharmaceuticals IncABOS
1Strong Buy$27.00N/AInitiates Coverage On
4 years ago
Prevail Therapeutics IncPRVL
1Strong Buy$23.00N/AInitiates Coverage On
5 years ago
Gw Pharmaceuticals PLCGWPH
4Hold$140.00N/ADowngrades
5 years ago
Avadel Pharmaceuticals PLCAVDL
1Strong Buy$14.00N/AInitiates Coverage On
6 years ago
Zogenix IncZGNX
3Buy$60.00N/AInitiates Coverage On
7 years ago
Acorda Therapeutics IncACORQ
1Hold$2,280.00N/AMaintains
7 years ago
Akcea Therapeutics IncAKCA
2Hold$31.00N/AMaintains
7 years ago
Obseva SaOBSVF
1Buy$18.00N/AMaintains
8 years ago
Wave Life Sciences LtdWVE
1Buy$64.00N/AMaintains
8 years ago
Cidara Therapeutics IncCDTX
1Buy$340.00N/AInitiates Coverage On
9 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.